Relieves inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. ANDA 205206, held by Zydus Lifesciences. Desoximetasone.
As of Nov 15, 2026, ANDA 205206 (Desoximetasone), held by Zydus Lifesciences, was first approved by FDA on Sep 19, 2017, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Desoximetasone Ointment USP, 0.25% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 19, 2017 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Desoximetasone0.25% · ointment;topical | Desoximetasone | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
